Viz.ai Receives First De Novo Approval by the FDA for Hypertrophic Cardiomyopathy AI Algorithm

New artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy

SAN FRANCISCO--(BUSINESS WIRE)--#ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received a De Novo approval by the U.S. Food and Drug Administration (FDA) for its Viz HCM module, a hypertrophic cardiomyopathy (HCM) artificial intelligence (AI) detection algorithm, creating a new regulatory category for cardiovascular machine learning-based notification software. The deployment of the algorithm is financially supported by a multi-year agreement with Bristol Myers Squibb (NYSE: BMY) announced in March. With the use of Viz HCM, which is integrated into the Viz.ai Platform, more patients with suspected HCM can be identified earlier using AI and triaged for diagnosis and further evaluation.

“Given the high prevalence of patients with suspected HCM who remain undiagnosed, flagging and connecting them quickly to the right providers is critical to improve health outcomes,” said Matthew Martinez, MD, director of sports cardiology and HCM, Atlantic Health System. “The role of artificial intelligence in cardiology is growing exponentially and adding the HCM module to Viz.ai will help increase awareness and reach for HCM patients.”

The Viz HCM module automatically reviews routine electrocardiograms (ECGs) from across a health system to identify suspected HCM cases and notifies the appropriate cardiologists and care team on the Viz mobile application. Clinicians can then easily review the patient’s ECG, coordinate follow-up with an echocardiogram for diagnosis, and use the Viz Echo Viewer to review images and access echocardiogram reports. The HCM module is one of twelve FDA-cleared AI algorithms on the enterprise-wide, clinically validated Viz.ai Platform, which has been shown to increase access to treatments and improve patient outcomes across more than 1,400 hospitals in the US and Europe.

“Hypertrophic cardiomyopathy is a devastating disease that is often undetected until it is too late. The addition of Viz HCM to the Viz.ai Platform aims to improve outcomes for patients with HCM by getting them to the right specialist faster,” said Chris Mansi, MD, CEO and co-founder at Viz.ai. “We are thrilled with this De Novo approval, which establishes the new FDA category of cardiovascular machine learning-based notification software. The ongoing investment of innovative capabilities on our platform is why it continues to be the first choice of leading healthcare systems. With our AI-powered Viz HCM module, we look forward to realizing its promise in expediting detection and care of patients with this common, inherited heart disease.”

To learn more about Viz HCM, please join our upcoming webinar on September 13 at 7pm ET.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,400+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz.ai Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Laurie Masonson
laurie.masonson@finnpartners.com